Ciclosporin (Cyclosporine)
Özet
Discovered in the 1970s, Cyclosporine is a strong immunosuppressive drug that is a calcineurin inhibitor and was first used to prevent transplant rejection after organ transplantation. It was approved for use in the treatment of psoriasis by the American Food and Drug Administration (FDA) in 1997. It was also approved for the treatment of atopic dermatitis in other countries. Besides these, cyclosporine is also used in the treatment of a wide range of dermatological diseases such as chronic urticaria, alopecia areata, pyoderma gangrenosum, lichen planus, Behçet’s disease, and photodermatoses. The use of cyclosporine in the geriatric population should be very carefully due to the increased risk of renal failure, cardiovascular comorbidities, polypharmacy and skin malignancy. Unlike the young population, it is recommended that intermittent treatment be preferred and that it is used for short periods of time in the geriatric population, should no longer than 12 weeks in continuous treatment due to side effects.
Referanslar
Amor KT, Ryan C,Menter A, The use of cyclosporine in dermatology: part I. J Am Acad Dermatol, 2010. 63(6): 925-46; quiz 947-8.
Amber T,Tabassum S, Cyclosporin in dermatology: A practical compendium. 2020. 33(6): e13934.
Dehesa L, Abuchar A, Nuno-Gonzalez A, Vitiello M,Kerdel FA, The use of cyclosporine in dermatology. J Drugs Dermatol, 2012. 11(8): 979-87.
Ryan C, Amor KT,Menter A, The use of cyclosporine in dermatology: part II. J Am Acad Dermatol, 2010. 63(6): 949-72; quiz 973-4.
Madan V,Griffiths CE, Systemic ciclosporin and tacrolimus in dermatology. Dermatol Ther, 2007. 20(4): 239-50.
Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR,Bhushan R, Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol, 2009. 61(3): 451-85.
Kovarik JM, Mueller EA, Johnston A, Hitzenberger G,Kutz K, Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation. Pharmacotherapy, 1993. 13(6): 613-7.
Cather JC, Abramovits W,Menter A, Cyclosporine and tacrolimus in dermatology. Dermatol Clin, 2001. 19(1): 119-37, ix.
Kolars JC, Awni WM, Merion RM,Watkins PB, First-pass metabolism of cyclosporin by the gut. Lancet, 1991. 338(8781): 1488-90.
Peter RU, Ruzicka T, Donhauser G,Braun-Falco O, Acrodermatitis continua-type of pustular psoriasis responds to low-dose cyclosporine. J Am Acad Dermatol, 1990. 23(3 Pt 1): 515-6.
Giavina-Bianchi M,Giavina-Bianchi P, Systemic Treatment for Severe Atopic Dermatitis. Arch Immunol Ther Exp (Warsz), 2019. 67(2): 69-78.
Zuberbier T, Ensina LF, Giménez-Arnau A, Grattan C, Kocatürk E, Kulthanan K, Kolkhir P,Maurer M, Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment. Lancet, 2024. 404(10450): 393-404.
Sánchez J, Alvarez L,Cardona R, Cyclosporine and omalizumab together: A new option for chronic refractory urticaria. J Allergy Clin Immunol Pract, 2020. 8(6): 2101-2103.
Callen JP,Jackson JM, Pyoderma gangrenosum: an update. Rheum Dis Clin North Am, 2007. 33(4): 787-802, vi.
Dissemond J, Marzano AV, Hampton PJ,Ortega-Loayza AG, Pyoderma Gangrenosum: Treatment Options. Drugs, 2023. 83(14): 1255-1267.
Dhurat R,Sharma R, A Practical Approach to the Treatment of Alopecia Areata. Indian Dermatol Online J, 2022. 13(6): 725-728.
Husein-ElAhmed H, Gieler U,Steinhoff M, Lichen planus: a comprehensive evidence-based analysis of medical treatment. J Eur Acad Dermatol Venereol, 2019. 33(10): 1847-1862.
Mrowietz U, Klein CE, Reich K, Rosenbach T, Ruzicka T, Sebastian M,Werfel T, Cyclosporine therapy in dermatology. J Dtsch Dermatol Ges, 2009. 7(5): 474-9.
Berth-Jones J, Exton LS, Ladoyanni E, Mohd Mustapa MF, Tebbs VM, Yesudian PD,Levell NJ, British Association of Dermatologists guidelines for the safe and effective prescribing of oral ciclosporin in dermatology 2018. Br J Dermatol, 2019. 180(6): 1312-1338.
Brown AL, Wilkinson R, Thomas TH, Levell N, Munro C, Marks J,Goodship TH, The effect of short-term low-dose cyclosporin on renal function and blood pressure in patients with psoriasis. Br J Dermatol, 1993. 128(5): 550-5.
Borghi A, Corazza M, Mantovani L, Bertoldi AM, Giari S,Virgili A, Prolonged cyclosporine treatment of severe or recalcitrant psoriasis: descriptive study in a series of 20 patients. Int J Dermatol, 2012. 51(12): 1512-6.
Silverman AK, Emmett M,Menter A, Can maintenance cyclosporine be used in psoriasis without decreasing renal function? Semin Dermatol, 1992. 11(4): 302-12.
Taler SJ, Textor SC, Canzanello VJ,Schwartz L, Cyclosporin-induced hypertension: incidence, pathogenesis and management. Drug Saf, 1999. 20(5): 437-49.
Lain EL,Markus RF, Early and explosive development of nodular basal cell carcinoma and multiple keratoacanthomas in psoriasis patients treated with cyclosporine. J Drugs Dermatol, 2004. 3(6): 680-2.
Behnam SM, Behnam SE,Koo JY, Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use. J Drugs Dermatol, 2005. 4(2): 189-94.
Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, Lamarque V,Dubertret L, Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol, 2003. 120(2): 211-6.
Väkevä L, Reitamo S, Pukkala E, Sarna S,Ranki A, Long-term follow-up of cancer risk in patients treated with short-term cyclosporine. Acta Derm Venereol, 2008. 88(2): 117-20.
Lebwohl M, Ellis C, Gottlieb A, Koo J, Krueger G, Linden K, Shupack J,Weinstein G, Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol, 1998. 39(3): 464-75.
Omar MA, Wilson JP,Cox TS, Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother, 2001. 35(9): 1096-107.
Berth-Jones J, The use of ciclosporin in psoriasis. J Dermatolog Treat, 2005. 16(5-6): 258-77.
Salman BN, Vahabi S, Movaghar SE,Mahjour F, Proliferative and inductive effects of Cyclosporine a on gingival fibroblast of child and adult. Dent Res J (Isfahan), 2013. 10(1): 52-8.
Seymour RA,Smith DG, The effect of a plaque control programme on the incidence and severity of cyclosporin-induced gingival changes. J Clin Periodontol, 1991. 18(2): 107-10.
Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Hönigsmann H, Hussain M, Jobling R, Karvonen SL, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne JP, Orzechowski HD, Rantanen T, Reich K, Reytan N, Richards H, Thio HB, van de Kerkhof P,Rzany B, European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol, 2009. 23 Suppl 2: 1-70.
Rosmarin DM, Lebwohl M, Elewski BE,Gottlieb AB, Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol, 2010. 62(5): 838-53.
Kovarik JM,Koelle EU, Cyclosporin pharmacokinetics in the elderly. Drugs Aging, 1999. 15(3): 197-205.
Ventura MT, Cassano N, Romita P, Vestita M, Foti C,Vena GA, Management of chronic spontaneous urticaria in the elderly. Drugs Aging, 2015. 32(4): 271-82.
Turnheim K, Drug therapy in the elderly. Exp Gerontol, 2004. 39(11-12): 1731-8.
Tanei R, Atopic Dermatitis in Older Adults: A Review of Treatment Options. Drugs Aging, 2020. 37(3): 149-160.
Kostović K, Žužul K, Čeović R,Bukvić Mokos Z, Psoriasis in the mature patient: Therapeutic approach in the era of biologics. Clin Dermatol, 2018. 36(2): 222-230.
